Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current or former smokers) non-small cell lung cancer

Veliparib is being developed as an improvement on previous drugs, for the treatment of advanced or metastatic non-squamous non-small cell lung cancer. In combination with carboplatin and paclitaxel it will, if licenced, offer an additional treatment option for patients with this indication.